Company: ZLAB
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001628280-25-020478
Chunk: 11

Company: Zai Lab Ltd
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 11
---
2022)

• Member of the Board of Directors and Chairman of the Audit Committee of Audentes Therapeutics, Inc. (NASDAQ) (2016-its sale to Astellas in January 2020)

• Director on several life sciences industry boards, including BIO ECS (2002-2006), the Bay Area Biosciences Board (now California Life Sciences) (1989-2012), the Biotechnology Institute (1998- 2012), and the Life Sciences Foundation (2014-its merger with the Chemical Heritage Foundation in 2015)

• Awarded the CLS Pantheon 2016 Life Sciences Leadership Award

• B.S. in Business Administration from the Haas School at University of California, Berkeley and Certified Public Accountant (inactive)

<div align='center'>-5-</div>

#### Leon Oliver Moulder, Jr.
Independent Director

| Age |     | Director Since |     | Board Committees                                                                                     |     | Other Public Company Boards                                         |
| 67  |     |           2020 |     | Nominating and Corporate Governance, Chair Compensation                                   Commercial |     | Zenas BioPharma, Inc. (NASDAQ) Dianthus Therapeutics, Inc. (NASDAQ) |

Mr. Moulder brings to the Board of Directors significant operational and senior management experience in the biopharmaceutical industry as well as extensive experience as a director on public and private boards in the industry.

#### Key Experience and Qualifications
• Founder and Managing Member of Tellus BioVentures, LLC, a life sciences investment fund (March 2019-Present)

• Founder and Chairman of the Board of Directors of Zenas BioPharma, Inc. (NASDAQ), a clinical-stage global biopharmaceutical company focused on developing and commercializing immunology-based therapies (December 2019-Present), also serving as Chief Executive Officer since August 2023

• Member of the Board of Directors of Dianthus Therapeutics, Inc. (NASDAQ), a clinical-stage biotechnology company (September 2023-Present)

• Chairman of the Board of Directors of Trevana, Inc. (2011-December 2023)

• Co-Founder, Chief Executive Officer, and Member of the Board Directors of Tesaro, Inc. (NASDAQ) (May 2010-its acquisition by GSK plc in January 2019)

• President, Chief Executive Officer, and Vice Chairman of the Board of Directors of Abraxis BioScience, Inc. (NASDAQ) (2009